Literature DB >> 29760024

An Updated Analysis of Direct-to-Consumer Television Advertisements for Prescription Drugs.

Janelle Applequist1, Jennifer Gerard Ball2.   

Abstract

PURPOSE: In 2015, the American Medical Association called for a ban of direct-to-consumer advertising (DTCA) for prescription drugs. Yet, the pharmaceutical industry spends more than ever on broadcast advertisements, with national health care costs largely driven by drug spending. An evaluation of these ads is critical, as these advertisements can impact the frequency which patients ask their doctors about medications.
METHODS: A content analysis of prime-time direct-to-consumer ads was conducted across 4 major cable television networks. The ad content (n = 61) was coded for factual claims made regarding target conditions, appeals used, portrayal of medications, and lifestyle characteristics shown.
RESULTS: We found a substantial decrease in the percentage of ads that conveyed information about the conditions being targeted, such as risk factors (16%) and prevalence (16%). Positive emotional appeals (94%) continued to be emphasized; yet there was decreased use of negative emotional appeals (51%), pointing to an overall more positive portrayal of a patient's experience with a medication. The lifestyles portrayed in the sample largely featured how products can enable more recreational activities (69%) and fewer ads (7%) presented alternatives to product use.
CONCLUSIONS: Direct-to-consumer advertising continued to promote prescription drugs above educating the population. Improvement in the educational value of DTCA is likely to require regulatory action rather than reliance on self-regulation by the pharmaceutical industry.
© 2018 Annals of Family Medicine, Inc.

Entities:  

Keywords:  DTC; DTCA; content analysis; direct-to-consumer advertising; pharmaceutical industry; prescription drug advertising

Mesh:

Substances:

Year:  2018        PMID: 29760024      PMCID: PMC5951249          DOI: 10.1370/afm.2220

Source DB:  PubMed          Journal:  Ann Fam Med        ISSN: 1544-1709            Impact factor:   5.166


  8 in total

1.  A meta-analysis of fear appeals: implications for effective public health campaigns.

Authors:  K Witte; M Allen
Journal:  Health Educ Behav       Date:  2000-10

2.  Consumers young and old: segmenting the target markets for direct-to-consumer prescription drug advertising.

Authors:  Jennifer Gerard Ball; Danae Manika; Patricia Stout
Journal:  Health Mark Q       Date:  2011-10

3.  Direct-to-consumer print ads for drugs: do they undermine the physician-patient relationship?

Authors:  Rebecca J Welch Cline; Henry J Young
Journal:  J Fam Pract       Date:  2005-12       Impact factor: 0.493

4.  Creating demand for prescription drugs: a content analysis of television direct-to-consumer advertising.

Authors:  Dominick L Frosch; Patrick M Krueger; Robert C Hornik; Peter F Cronholm; Frances K Barg
Journal:  Ann Fam Med       Date:  2007 Jan-Feb       Impact factor: 5.166

5.  Time to ban direct-to-consumer prescription drug marketing.

Authors:  Kurt C Stange
Journal:  Ann Fam Med       Date:  2007 Mar-Apr       Impact factor: 5.166

6.  DTC advertising harms patients and should be tightly regulated.

Authors:  Peter Lurie
Journal:  J Law Med Ethics       Date:  2009       Impact factor: 1.718

7.  A Protection Motivation Theory of Fear Appeals and Attitude Change1.

Authors:  Ronald W Rogers
Journal:  J Psychol       Date:  1975-09

8.  A decade of controversy: balancing policy with evidence in the regulation of prescription drug advertising.

Authors:  Dominick L Frosch; David Grande; Derjung M Tarn; Richard L Kravitz
Journal:  Am J Public Health       Date:  2010-01       Impact factor: 9.308

  8 in total
  6 in total

1.  Impact of direct-to-consumer drug advertising during the Super Bowl on drug utilization.

Authors:  Matthew P Gray; Alvaro San-Juan-Rodriguez; Nemin Chen; Chester B Good; Inmaculada Hernandez
Journal:  Res Social Adm Pharm       Date:  2019-12-09

2.  Content Analysis of 2012-2019 FDA Warning Letters and Notices of Violations using the Economic, Clinical, and Humanistic Outcomes (ECHO) Model.

Authors:  Namosha Mohite; Vienica Funtanilla; Jagannath Muzumdar; Taehwan Park
Journal:  Innov Pharm       Date:  2021-01-13

3.  Physicians Treating Alzheimer's Disease Patients Should Be Aware that Televised Direct-to-Consumer Advertising Links More Strongly to Drug Utilization in Older Patients.

Authors:  Robin Feldman
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

4.  A novel approach to conducting clinical trials in the community setting: utilizing patient-driven platforms and social media to drive web-based patient recruitment.

Authors:  Janelle Applequist; Cristina Burroughs; Artemio Ramirez; Peter A Merkel; Marc E Rothenberg; Bruce Trapnell; Robert J Desnick; Mustafa Sahin; Jeffrey P Krischer
Journal:  BMC Med Res Methodol       Date:  2020-03-13       Impact factor: 4.615

5.  Communicative and Discursive Perspectives on the Medication Experience.

Authors:  Lewis H Glinert
Journal:  Pharmacy (Basel)       Date:  2021-02-17

6.  Does price disclosure in pharmaceutical advertising result in price transparency? Evidence from a randomized experiment.

Authors:  Ilene L Hollin; Jennifer Gerard Ball
Journal:  Explor Res Clin Soc Pharm       Date:  2022-09-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.